News

BRAINBox Solutions Announces Appointment of Richard H. Noel as Chief Product and Commercial Officer

BRAINBox Solutions today announced the appointment of Richard H. Noel to the newly created position of Chief Product and Commercial Officer. Richard brings more than 10 years of experience in molecular and point-of-care diagnostics, at Roche Diagnostics, LumiraDx, and bioMérieux.

“Richard, whose expertise spans market analytics, global product management, and senior commercial leadership, has established a strong track record at leading diagnostics companies,” said Donna Edmonds, BRAINBox Solutions CEO. “He is well positioned to lead the commercial planning and launch for our BRAINBox TBI concussion diagnostic/prognostic tests.”

“BRAINBox has a unique opportunity to change the standard of care for concussion management with its BRAINBox TBI tests, the first objective tests for the diagnosis and risk of long-term complications,” said Mr. Noel. “The company has built an outstanding foundation with product and clinical development and strong relationships with key thought leaders in neurology and emergency medicine. I look forward to working with the team to bring these promising tests to clinicians and patients.”

Mr. Noel began his career in diagnostics at bioMérieux as a market analyst in the BioFire diagnostics unit, rising to Global Product Manager, where he served as global product leader for numerous syndromic molecular diagnostic panels, analyzers and software solutions. At Lumira, he served as Senior Director of Marketing, North America, where he led the marketing strategy and launch of the company’s novel SARS-CoV-2 Ag test during the Covid pandemic. He spearheaded the marketing strategy for the company’s North American point-of-care business, launching and scaling it from $0 to $440 million in revenue within 24 months. Following LumiraDx’s acquisition by Roche Diagnostics in 2024, he guided the full integration of the LumiraDx commercial business and roadmap.

Before entering the diagnostics industry, Mr. Noel taught honors physics, chemistry, and cognitive neuroscience. He holds a Master’s degree in Business and Biotechnology from the University of Utah and a Bachelor’s degree in Psychology from UC San Diego.

Read more here.

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business